Shibata Ken, Iwatani Kosuke, Imai Y U, Yoshihara Kentaro, Miyajima Keiichiro, Fukuokaya Wataru, Ito Kagenori, Igarashi Taro, Yanagisawa Takafumi, Tashiro Kojiro, Tsuzuki Shusuke, Yuen Steffi Kar Kei, Teoh Jeremy Yuen-Chun, Yanada Brendan A, Koike Yusuke, Shimomura Tatsuya, Yamada Hiroki, Furuta Akira, Miki Jun, Kimura Takahiro, Urabe Fumihiko
Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Department of Urology, Jikei University Kashiwa Hospital, Chiba, Japan.
In Vivo. 2025 Mar-Apr;39(2):824-833. doi: 10.21873/invivo.13885.
BACKGROUND/AIM: The lung immune prognostic index (LIPI), which is determined by assessing the derived neutrophil-to-lymphocyte ratio in conjunction with the level of lactate dehydrogenase, predicts outcomes in various cancers. Its utility as a preoperative biomarker in upper tract urothelial carcinoma (UTUC) patients remains unexplored.
This is a retrospective study of UTUC patients who underwent radical nephroureterectomy. Patients were stratified into favorable, intermediate, and poor LIPI groups. Non-urothelial tract recurrence-free survival (NUTRFS) was evaluated using Kaplan-Meier analysis, and Cox regression analyses were performed to identify risk factors for NUTRFS.
A total of 567 UTUC patients were included, with 46.4% in the favorable, 44.6% in the intermediate, and 9.0% in the poor (9.0%) LIPI groups. The median participant age was 74 years, with a median follow-up of 26 months. Kaplan-Meier curves demonstrated that NUTRFS was significantly worse in patients with poor and intermediate LIPI scores than in those with favorable LIPI scores. Furthermore, combining LIPI status with pathological stages (pT3-4/ypT2-4) and lymph node metastasis status improved postoperative non-urothelial tract recurrence prognosis assessment.
The preoperative LIPI is a prognostic indicator for patients with UTUC undergoing nephroureterectomy. Its predictive accuracy improves when combined with advanced pathological stages and lymph node metastasis status.
背景/目的:肺免疫预后指数(LIPI)通过评估衍生的中性粒细胞与淋巴细胞比率并结合乳酸脱氢酶水平来确定,可预测多种癌症的预后。其作为上尿路尿路上皮癌(UTUC)患者术前生物标志物的效用仍未得到探索。
这是一项对接受根治性肾输尿管切除术的UTUC患者的回顾性研究。患者被分为LIPI良好、中等和不良组。使用Kaplan-Meier分析评估非尿路无复发生存期(NUTRFS),并进行Cox回归分析以确定NUTRFS的危险因素。
共纳入567例UTUC患者,LIPI良好组占46.4%,中等组占44.6%,不良组占9.0%。参与者的中位年龄为74岁,中位随访时间为26个月。Kaplan-Meier曲线表明,LIPI评分不良和中等的患者的NUTRFS明显比LIPI评分良好的患者差。此外,将LIPI状态与病理分期(pT3-4/ypT2-4)和淋巴结转移状态相结合可改善术后非尿路复发预后评估。
术前LIPI是接受肾输尿管切除术的UTUC患者的预后指标。与晚期病理分期和淋巴结转移状态相结合时,其预测准确性会提高。